Literature DB >> 29631076

Metabolic profiling of corylin in vivo and in vitro.

Zifei Qin1, Shishi Li2, Zhihong Yao3, Xiaodan Hong2, Jinjin Xu2, Pei Lin2, Guoping Zhao4, Frank J Gonzalez5, Xinsheng Yao6.   

Abstract

Corylin, an phenolic compound from Psoralea corylifolia, has been reported with various pharmacological properties but has poor bioavailability due to massive metabolism. In this study, twelve metabolites of corylin mainly involving in oxidation, hydration, glucuronidation and sulfation were detected in mice. Furthermore, the oxidation and hydration of corylin (M4) in human liver microsomes (HLM) and human intestine microsomes (HIM) were both efficient with high CLint (intrinsic clearance) values of 24.29 and 42.85 μL/min/mg, respectively. CYP1A1, 1B1 and 2C19 contributed most for M4 with the CLint values of 26.63, 33.09 and 132.41 μL/min/mg, respectively. Besides, M4 was strongly correlated with phenacetin-N-deacetylation (r = 0.885, p = 0.0001) and tolbutamide-4-oxidation (r = 0.727, p = 0.001) in twelve individual HLMs, respectively. In addition, corylin was efficiently glucuronidated (M7) in HLM (125.33 μL/min/mg) and in HIM (108.74 μL/min/mg). UGT1A1 contributed the most for M7 with the CLint value of 122.32 μL/min/mg. Meanwhile, M7 was significantly correlated with β-estradiol-3-O-glucuronidation (r = 0.742, p = 0.006) in twelve individual HLMs. Moreover, the metabolism of corylin showed marked species differences. Taken together, corylin was subjected to massive first-pass metabolism in liver and intestine, while CYP1A1, 1B1, 2C19 and UGT1A1 were the main contributors. Finally, the proposed metabolic pathway of corylin involed CYP and UGT isoforms were summarized, which could help to understand the metabolic fate of corylin in vivo.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Corylin; Cytochromes P450; Metabolites profile; Species differences; UDP-glucuronosyltransferase

Mesh:

Substances:

Year:  2018        PMID: 29631076      PMCID: PMC6666405          DOI: 10.1016/j.jpba.2018.03.047

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  31 in total

Review 1.  Atypical kinetic profiles in drug metabolism reactions.

Authors:  J Matthew Hutzler; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2002-04       Impact factor: 3.922

Review 2.  Assessment of in silico models for fraction of unbound drug in human liver microsomes.

Authors:  Hua Gao; Stefanus J Steyn; George Chang; Jing Lin
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-05       Impact factor: 4.481

3.  Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement.

Authors:  David Hallifax; J Brian Houston
Journal:  Drug Metab Dispos       Date:  2006-04       Impact factor: 3.922

Review 4.  Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.

Authors:  Swati Nagar; Rebecca L Blanchard
Journal:  Drug Metab Rev       Date:  2006       Impact factor: 4.518

5.  Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes.

Authors:  Patrick Poulin; Sami Haddad
Journal:  J Pharm Sci       Date:  2011-05-13       Impact factor: 3.534

Review 6.  Pharmacogenetics of irinotecan disposition and toxicity: a review.

Authors:  Ken-ichi Fujita; Alex Sparreboom
Journal:  Curr Clin Pharmacol       Date:  2010-08

7.  Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites.

Authors:  Jin Zhou; Timothy S Tracy; Rory P Remmel
Journal:  Drug Metab Dispos       Date:  2009-12-09       Impact factor: 3.922

Review 8.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction.

Authors:  Shuji Ohno; Shizuo Nakajin
Journal:  Drug Metab Dispos       Date:  2008-10-06       Impact factor: 3.922

10.  The human intestinal cytochrome P450 "pie".

Authors:  Mary F Paine; Heather L Hart; Shana S Ludington; Robert L Haining; Allan E Rettie; Darryl C Zeldin
Journal:  Drug Metab Dispos       Date:  2006-02-07       Impact factor: 3.922

View more
  10 in total

1.  Metabolism and disposition of corylifol A from Psoralea corylifolia: metabolite mapping, isozyme contribution, species differences and identification of efflux transporters for corylifol A-O-glucuronide in HeLa1A1 cells.

Authors:  Yang Li; Jinjin Xu; Chunxia Xu; Zifei Qin; Shishi Li; Liufang Hu; Zhihong Yao; Frank J Gonzalez; Xinsheng Yao
Journal:  Xenobiotica       Date:  2020-04-01       Impact factor: 1.908

2.  In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry.

Authors:  Jinjin Xu; Mengsen Li; Zhihong Yao; Yezi Zhang; Shishi Li; Liufang Hu; Zifei Qin; Frank J Gonzalez; Xinsheng Yao
Journal:  J Pharm Biomed Anal       Date:  2018-06-18       Impact factor: 3.935

3.  Potential metabolism determinants and drug-drug interactions of a natural flavanone bavachinin.

Authors:  Xinqiang Li; Han Xing; Zifei Qin; Jing Yang; Peile Wang; Xiaojian Zhang; Zhihong Yao; Xinsheng Yao
Journal:  RSC Adv       Date:  2020-09-23       Impact factor: 4.036

4.  Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System.

Authors:  Zu-Guo Zheng; Xin Zhang; Xiao-Xiao Liu; Xiu-Xiu Jin; Lunzhi Dai; Hui-Min Cheng; Dan Jing; Pyone Myat Thu; Mu Zhang; Hongyang Li; Jing Zhu; Chang Liu; Bin Xue; Yu Li; Ligong Chen; Cheng Peng; Weiliang Zhu; Lin Wang; Junli Liu; Hui-Jun Li; Ping Li; Xiaojun Xu
Journal:  Theranostics       Date:  2019-08-12       Impact factor: 11.556

Review 5.  Recent Analytical Approaches for the Study of Bioavailability and Metabolism of Bioactive Phenolic Compounds.

Authors:  Álvaro Fernández-Ochoa; María de la Luz Cádiz-Gurrea; Patricia Fernández-Moreno; Alejandro Rojas-García; David Arráez-Román; Antonio Segura-Carretero
Journal:  Molecules       Date:  2022-01-25       Impact factor: 4.411

6.  An investigation of the metabolic activity, isozyme contribution, species differences and potential drug-drug interactions of PI-103, and the identification of efflux transporters for PI-103-O-glucuronide in HeLa1A9 cells.

Authors:  Li Gao; Zifei Qin; Beibei Zhang; Zhao Yin; Xiaojian Zhang; Jing Yang
Journal:  RSC Adv       Date:  2020-03-05       Impact factor: 4.036

7.  Identification of naturally occurring inhibitors in Xian-Ling-Gu-Bao capsule against the glucuronidation of estrogens.

Authors:  Liangliang He; Chunxia Xu; Ziying Wang; Shuyi Duan; Jinjin Xu; Chuan Li; Xinsheng Yao; Frank J Gonzalez; Zifei Qin; Zhihong Yao
Journal:  Front Pharmacol       Date:  2022-08-04       Impact factor: 5.988

8.  Investigation on the metabolic characteristics of isobavachin in Psoralea corylifolia L. (Bu-gu-zhi) and its potential inhibition against human cytochrome P450s and UDP-glucuronosyltransferases.

Authors:  Han Xing; Jing Yang; Kaidi Ren; Zifei Qin; Peile Wang; Xiaojian Zhang; Zhihong Yao; Frank J Gonzalez; Xinsheng Yao
Journal:  J Pharm Pharmacol       Date:  2020-08-04       Impact factor: 4.810

9.  Characterization of metabolic activity, isozyme contribution and species differences of bavachin, and identification of efflux transporters for bavachin-O-glucuronide in HeLa1A1 cells.

Authors:  Yang Li; Chunxia Xu; Jinjin Xu; Zifei Qin; Shishi Li; Liufang Hu; Zhihong Yao; Frank J Gonzalez; Xinsheng Yao
Journal:  J Pharm Pharmacol       Date:  2020-07-09       Impact factor: 4.810

10.  Corylin inhibits LPS-induced inflammatory response and attenuates the activation of NLRP3 inflammasome in microglia.

Authors:  Ming-Yii Huang; Chia-En Tu; Shu-Chi Wang; Yung-Li Hung; Chia-Cheng Su; Shih-Hua Fang; Chi-Shuo Chen; Po-Len Liu; Wei-Chung Cheng; Yu-Wei Huang; Chia-Yang Li
Journal:  BMC Complement Altern Med       Date:  2018-08-15       Impact factor: 3.659

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.